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HMGB1 and the recently described interleukin-33 (IL-33) are abundant chromatin-associated nuclear
factors with potent proinflammatory cytokine activities. In this issue of Chemistry & Biology, Mollica
et al. [1] report the identification of the first direct small-molecule inhibitor of HMGB1.Cytokines play a major role in a wide
range of inflammatory, infectious, and
autoimmune diseases. In 1999, K.J.
Tracey and colleagues discovered
that the abundant chromatin-associ-
ated protein HMGB1 is secreted by
activated macrophages during inflam-
mation, and plays a critical role as
a late mediator of lethal endotoxemia
and sepsis [2]. Since this initial report,
the cytokine activity of HMGB1 has
been confirmed by many groups and
HMGB1 has now been proposed to
be a crucial mediator in the patho-
genesis of many diseases including
sepsis, arthritis, and cancer [3, 4].
The identification of HMGB1 inhibitors
or antagonists is therefore of great
therapeutic interest.
IL-33, themost recent addition to the
IL-1 family, is a potent proinflammatory
cytokine that induces production of
Th2-associated cytokines IL-4, IL-5,
and IL-13, both in vitro and in vivo
[5]. Surprisingly, IL-33 has also been
described as an abundant chromatin-
associated nuclear factor, which asso-
ciates with mitotic chromosomes in
living cells and with interphase chro-
matin in the nucleus of endothelial cells
in vivo [6, 7]. IL-33 therefore constitutes
a second example of a chromatin-
associated cytokine.
There are a number of different
approaches that can be used to target
chromatin-associated cytokines (Fig-
ure 1). These include production of
biological agents, (i.e., function-blocking
antibodies, peptide antagonists, and
soluble receptors), as well as synthesis
of small-molecule chemical inhibitors.
HMGB1-specific antibodies have been
shown to protect mice against endo-
toxin and sepsis lethality [2, 8]. Similar
protective effects were observed withHMGB1 A box peptide, a competitive
antagonist of HMGB1 cytokine activity
[8]. Antibodies against HMGB1 or re-
combinant A box peptide have also
been found to ameliorate the symp-
toms of collagen-induced arthritis [9].
Humanized anti-HMGB1 monoclonal
antibodies that are currently under
development may therefore find appli-
cations in both acute and chronic
inflammatory diseases. Although neu-
tralizing antibodies and antagonistic
peptides for IL-33 are not yet available,
a soluble IL-33 (ST2) receptor has
been generated. It has exhibited thera-
peutic efficacy in several experimental
disease models in vivo, including
collagen-induced arthritis [10] and
allergic asthma associated with Th2
responses [11].
In addition to the biological agents,
there are several small-molecule
chemical compounds that have been
used to inhibit HMGB1 proinflamma-
tory activities in vivo. These pharma-
cological agents, which belong to the
class of cytokine-release inhibitory
drugs (CRIDs) and include ethyl pyru-
vate [12], cholinergic agonists nicotine
and acetylcholine [13], stearoyl lyso-
phosphatidylcholine [14], and steroid-
like pigment tanshinone IIA [15], have
been shown to interfere specifically
with HMGB1 release from the nucleus
into the extracellular space, without
affecting its mRNA or protein levels
[12, 13]. In contrast, many other steroi-
dal drugs (such as dexamethasone
and cortisone) and nonsteroidal anti-
inflammatory drugs (such as aspirin,
ibuprofen, and indomethacin) failed
to inhibit HMGB1 extracellular release
significantly [15]. Mechanistic studies
with endotoxin-activated monocytes
and macrophages revealed thatChemistry & Biology 14, April 2007 ªHMGB1 CRIDs block cytoplasmic
translocation of HMGB1 [13–15], the
first step in its extracellular secretion
[16]. The HMGB1 CRIDs have shown
impressive efficacy in animal models
of lethal endotoxemia and sepsis [12–
15] and the protective effects occurred
in therapeutically achievable, safe
doses [12, 15], supporting the thera-
peutic potential of these inhibitors in
HMGB1-mediated human inflamma-
tory diseases. Unfortunately, nothing
is known yet about the mechanisms
of IL-33 release from chromatin [6]
and IL-33 CRIDs are not yet available.
In this issue of Chemistry & Biology,
Mollica et al. [1] report the identifica-
tion of glycyrrhizin, a natural anti-
inflammatory and antiviral triterpene
in clinical use, as a novel pharmaco-
logical inhibitor of HMGB1 cytokine
activities. The authors show that gly-
cyrrhizin, which is produced by the lic-
orice plant Glycyrrhiza glabra, inhibits
the chemotactic and mitogenic activi-
ties of HMGB1. Importantly, they dem-
onstrate that glycyrrhizin binds directly
to HMGB1 and identify its binding sur-
face on HMGB1 using state of the art
NMR chemical shift difference map-
ping. They also provide binding con-
stants and three-dimensional models
of the glycyrrhizin:HMGB1 complex.
Surprisingly, despite the fact the
glycyrrhizin binding sites on HMGB1
(helix 1 and 2 in the HMG boxes) par-
tially overlap with the DNA binding
sites (Figure 1), glycyrrhizin interferes
only mildly with the binding of HMGB1
to DNA in living cells.
These results are important because
they convincingly demonstrate that
glycyrrhizin is a direct inhibitor of
HMGB1 and that its mechanism of ac-
tion is different from those of HMGB12007 Elsevier Ltd All rights reserved 345
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from the nucleus into the extracellular
space, but do not bind directly to
HMGB1 and thus can’t block its extra-
cellular functions. In contrast, glycyr-
rhizin does not interfere with HMGB1
release, but can directly inhibit its
extracellular cytokine activities. Inter-
estingly, biologically active HMGB1
has been shown to be passively re-
leased by necrotic or damaged cells,
in addition to being secreted by acti-
vated macrophages [17]. Glycyrrhizin,
which binds directly to HMGB1, can
potentially block HMGB1 released
into the extracellular space by the
two distinct mechanisms, while
HMGB1 CRIDs only interfere with the
release of HMGB1 by activated inflam-
matory cells (Figure 1). Direct small-
molecule inhibitors of HMGB1, such
as glycyrrhizin, may therefore exhibit
greater therapeutic potential than
HMGB1 CRIDs.
Of note, glycyrrhizin is commonly
used in Japan to treat patients with
chronic hepatitis and in a related
study, M.E. Bianchi and colleagues
have shown that glycyrrhizin reduces
liver disease in a mouse model of
hepatitis B by interfering with HMGB1-
induced recruitment of neutrophils and
other inflammatory cells in the liver
[18]. The inhibitory effects of glycyrrhi-
Figure 1. Chromatin-Associated Cytokine HMGB1 and Strategies to Inhibit Its
Proinflammatory Activities
(A) HMGB1 and IL-33 are abundant chromatin-associated nuclear factors that possess potent
proinflammatory cytokine activities. The identification of HMGB1 and IL-33 inhibitors is therefore
of great therapeutic interest.
(B) Human HGMB1. The two DNA-binding HMG boxes (A and B boxes) and the acidic C terminus
are indicated. The B box mediates HMGB1 cytokine activities. In contrast, the A box is a compet-
itive antagonist of HMGB1 extracellular functions. Glycyrrhizin binds to two homologous sites in
the A and B HMG boxes [1].
(C) Strategies for HMGB1 inhibition. Small-molecule inhibitors include the cytokine release inhibi-
tory drugs (CRIDs) and the direct inhibitor glycyrrhizin. Biological agents include anti-HMGB1
antibodies and the recombinant A box peptide antagonist. Glycyrrhizin and the biologics can
inhibit HMGB1 released by both activated macrophages and necrotic cells. In contrast, HMGB1
CRIDs only block the release of HMGB1 from activated monocytes/macrophages.346 Chemistry & Biology 14, April 2007 ª2007 Elsevier Ltd All rights reservedzin in this model were similar to those
of recombinant A box peptide, further
supporting a direct inhibitory effect of
glycyrrhizin on extracellular HMGB1.
The NMR chemical shift difference
method used by Mollica and col-
leagues proved to be very useful for
mapping the two glycyrrhizin binding
sites on HMGB1 (DNA binding HMG
boxes A and B) and for modelling gly-
cyrrhizin interaction with these sites
[1]. The affinity of glycyrrhizin for
HMGB1 is relatively modest (Kd 
150 mM) and will need to be further
improved for any therapeutic applica-
tion. The three-dimensional molecular
model of the glycyrrhizin:HMGB1
complex provided by the authors is
very likely to be useful in this respect.
Hopefully, it will open the way to the
design of new glycyrrhizin derivatives
with improved HMGB1 binding and
anti-inflammatory properties in vivo.
Finally, it will be interesting to see
whether a similar approach can be
applied to the identification of small-
molecule inhibitors targeting IL-33. A
direct chemical inhibitor of IL-33 would
undoubtedly be of great pharmaceuti-
cal interest for the therapy of human
inflammatory diseases.
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high hit rates.
In this issue of Chemistry & Biology,
Waldmann and colleagues report on
the discovery of new modulators of
cell cycle progression and viral entry
through cellular screening of a natu-
ral-product-derived compound library
[1]. This library was built around a
a,b-unsaturated d-lactone scaffold,
which is a frequently encountered
structural motif in biologically active
natural products (Figure 1). Screening
was conducted using fluorescence-
based cellular assays that scored for
effects on the actin or microtubule
cytoskeleton, or, in a second case, for
inhibition of cellular entry of the vesic-
ular stomatitis virus (VSV). Remarkably,
several compounds with activities in
the low mM concentration range could
be identified in both assay systems, in
spite of a library size of only 50 com-
pounds. Compared to conventional
HTS campaigns, this is a spectacular
hit rate. Two of the compounds that
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l natural-product-derived library
synthesis on a solid support [1
w modulators of cell cycle progre
gression assay were subsequently
demonstrated to inhibit tubulin poly-
merization in vitro, thus linking the
activity observed at the cellular level
to a specificmolecular target (although
other targets may still contribute to the
overall cellular phenotype).
Based on this short factual sum-
mary, the paper would appear to de-
scribe what nowadays might be called
a ‘‘typical’’ chemical biology project,
namely the screening of a library
of low-molecular-weight synthetic
compounds in fluorescence-based,
phenotypic cellular assays followed
(sometimes) by the analysis of hit com-
pounds in target-specific systems.
However, the paper is not just a ‘‘typi-
cal’’ (yet important) manifestation of
modern chemical biology research. It
is particularly notable for the concep-
tual framework that forms the basis
for library design and synthesis and
for Waldmann’s research in general
[2, 3]. The dissection of the overall
Chemistry & Biology 14, April 2007 ª215. Li, W., Li, J., Ashok, M., Wu, R., Chen, D.,
Yang, L., Yang, H., Tracey, K.J., Wang,
P., Sama, A.E., et al. (2007). J. Immunol.
178, 3856–3864.
16. Bonaldi, T., Talamo, F., Scaffidi, P.,
Ferrera, D., Porto, A., Bachi, A., Rubartelli,
A., Agresti, A., and Bianchi, M.E. (2003).
EMBO J. 22, 5551–5560.
17. Scaffidi, P., Misteli, T., and Bianchi, M.E.
(2002). Nature 418, 191–195.
18. Sitia, G., Iannacone, M., Muller, S.,
Bianchi, M.E., and Guidotti, L.G. (2007).
J. Leukoc. Biol. 81, 100–107.nted Synthesis
ogy (ETH) Zu¨rich, HCI H 405,
of a,b-unsaturated d-lactones
]. Phenotypic screening of this
ssion and of viral cell entry with
concept underlying Waldmann’s ap-
proach to the identification of new
tool compounds for chemical biology
research and new lead structures for
drug discovery reveals three essential
ingredients (apart from the use of
powerfulscreeningtechnology),whose
combination now has been demon-
strated repeatedly to enable the effi-
cient identification of potent and spe-
cific inhibitors of various biological
targets [2, 3].
The first of these ingredients is the
idea that natural products represent
prevalidated lead structures for chem-
ical biology and medicinal chemistry
research, due to an inherent propen-
sity for protein binding. In other words,
natural products are good starting
points for the discovery of ligands for
virtually any protein, as they have
evolved to do precisely this, bind to
proteins, either during their own bio-
synthesis or through their involvement
in the modulation of a vast array of
007 Elsevier Ltd All rights reserved 347
